Therapy News and Research

RSS

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

16 Dec 2014

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).

15 Dec 2014

Novel marker may help doctors choose most effective treatment for older patients with AML

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML).

15 Dec 2014

Wearable technology and data analytics in healthcare: an interview with Mark Taglietti and Bob Zemke

Wearables is very much an emerging trend and healthcare is leading this effort. Consumer technology, such as the FitBit, Jawbone, and others, are going to merge with medical devices that are already being used in hospitals today.

15 Dec 2014

UT Southwestern researchers identify possible therapy to treat neurofibromatosis type 1

UT Southwestern Medical Center researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1, a childhood neurological disease characterized by learning deficits and autism that is caused by inherited mutations in the gene encoding a protein called neurofibromin.

15 Dec 2014

New holistic approach to cancer treatment

The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center.

15 Dec 2014

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Cervical cancer is, in many ways, a shining example of how successful the war on cancer can be. Thanks largely to the advent of Pap smear screening, U.S. cervical cancer deaths decreased dramatically, by more than 60 percent, between 1955 and 1992. In the last two decades, better treatment outcomes and more powerful imaging techniques have steadily pushed 5-year survival rates ever higher.

15 Dec 2014

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.

15 Dec 2014

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Back pain is exceptionally common. In fact, to not experience back pain at some point of your life would be thoroughly abnormal. Experiencing back pain is like becoming tired or becoming sad; we don’t necessarily like it, but it’s perfectly common.

14 Dec 2014

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial.

14 Dec 2014

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout.

14 Dec 2014

Apheresis: A potent therapeutic in extracorporeal photopherisis

Apheresis, the simple process of drawing blood, becomes a powerful therapeutic in extracorporeal photopherisis (ECP) according to clinicians and scientists who met at the NIH State of the Science Symposium in Therapeutic Apheresis. Nora Ratcliffe, MD, of Dartmouth Hitchcock, looked at current methodology and opportunities for research in a paper recently published in Transfusion Medicine Review, titled "National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis."

14 Dec 2014

Midazolam drug helps recover full consciousness in traumatic brain injury patient

A patient who had suffered a traumatic brain injury unexpectedly recovered full consciousness after the administration of midazolam, a mild depressant drug of the GABA A agonists family.

14 Dec 2014

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence of impaired mental function.

14 Dec 2014

People need to watch distinct warning signs of holiday depression

While the holidays are a time of merriment and festivities for many, some people struggle with depression during this time of year.

14 Dec 2014

Penn researchers find effective way to inhibit inflammatory response during kidney dialysis

Frequent kidney dialysis is essential for the approximately 350,000 end-stage renal disease (ESRD) patients in the United States. But it can also cause systemic inflammation, leading to complications such as cardiovascular disease and anemia, and patients who rely on the therapy have a five-year survival rate of only 35 percent. Such inflammation can be triggered when the complement cascade, part of the body's innate immune system, is inadvertently activated by modern polymer-based dialysis blood filters.

14 Dec 2014

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women.

14 Dec 2014

ALS Association announces research funds to further understand genetic cause of ALS

The ALS Association is pleased to announce the award of $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

HDM introduces new Z1 Auto CPAP that customizes therapy by monitoring pressure requirements

On Friday, December 12, 2014 Human Design Medical, LLC (HDM) announced its Z1 Auto CPAP, which makes a quantum leap forward in CPAP therapy. The new Z1 Auto customizes therapy for each individual by monitoring pressure requirements thousands of times per night. Unlike fixed pressure CPAP devices, the Z1 Auto automatically responds to changes in breathing patterns and delivers maximum comfort by using the lowest possible therapy pressure throughout the sleep cycle.

13 Dec 2014

Therapy News and Research

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

FL118 agent shows efficacy as personalized, targeted therapy for certain cancer tumors

Novel marker may help doctors choose most effective treatment for older patients with AML

Wearable technology and data analytics in healthcare: an interview with Mark Taglietti and Bob Zemke

UT Southwestern researchers identify possible therapy to treat neurofibromatosis type 1

New holistic approach to cancer treatment

Photoacoustic imaging has potential to be used as noninvasive method to detect cervical cancer

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

Apheresis: A potent therapeutic in extracorporeal photopherisis

Midazolam drug helps recover full consciousness in traumatic brain injury patient

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

People need to watch distinct warning signs of holiday depression

Penn researchers find effective way to inhibit inflammatory response during kidney dialysis

Study sheds light on clinical and biological characteristics of male breast cancer

ALS Association announces research funds to further understand genetic cause of ALS

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

HDM introduces new Z1 Auto CPAP that customizes therapy by monitoring pressure requirements

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News